



	ra Dr. Yugam Chopra crobiology) MD (Pathology) ant Pathologist CEO & Consultant Pathologist					
NAME : Mr. AN	IL MALHOTRA					
AGE/ GENDER : 55 YRS/	'MALE	РАТ	TENT ID	: 1755291		
DLLECTED BY :		REG. NO./LAB NO.		: 012502130009		
EFERRED BY :		REGISTRATION DATE		: 13/Feb/2025 09:12 AM		
BARCODE NO. : 015254	15	COLLECTION DATE		: 13/Feb/2025 09:16AM		
CLIENT CODE. : KOS DIA	AGNOSTIC LAB	REPORTING DATE		: 13/Feb/2025 01:58PM		
	, 1101101101100110, 1111					
Test Name		Value	Unit	Biological Reference inter		
GLYCOSYLATED HAEMOGLOBIN (HbA1c): WHOLE BLOOD by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY) ESTIMATED AVERAGE PLASMA GLUCOSE by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY) INTERPRETATION:		7 ^H 154.2 ^H	% mg/dL	4.0 - 6.4 60.00 - 140.00		
	AS PER AMERICAN DI	ABETES ASSOCIATIO	N (ADA)·			
REFERENCE (REFERENCE GROUP		GLYCOSYLATED HEMOGLOGIB (HBAIC) in %			
Non diabetic Adults >= 18 years		<5.7				
At Risk (Predi	,	5.7-6.4				
Diagnosing D	labetes	s >= 6.5 Age > 19 Years				
		Goals of Therapy: < 7.0		< 7.0		
Therapeutic goals for	glycemic control	Actions Suggested:		>8.0		
		Age < 19 Years Goal of therapy:		<7.5		

KOS Diagnostic Lab

(A Unit of KOS Healthcare)

 z_{1} and z_{2} shows the significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targetting a goal of < 7.0% may not be appropriate.

4. High HbA1c (>9.0 -9.5 %) is strongly associated with risk of development and rapid progression of microvascular and nerve complications 5. Any condition that shorten RBC life span like acute blood loss, hemolytic anemia falsely lower HbA1c results.

6.HbA1c results from patients with HbSS,HbSC and HbD must be interpreted with caution, given the pathological processes including anemia, increased red cell turnover, and transfusion requirement that adversely impact HbA1c as a marker of long-term gycemic control.

7. Specimens from patients with polycythemia or post-splenctomy may exhibit increse in HbA1c values due to a somewhat longer life span of the red cells.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt - 133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt - 133 001, Haryana 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT.



		Chopra y & Microbiology) Consultant Pathologist	Dr. Yugam (MD (P CEO & Consultant Pa	athology)
AME	: Mr. ANIL MALHOTRA			
GE/ GENDER	: 55 YRS/MALE	PATIE	ENT ID	: 1755291
OLLECTED BY	:	REG. N	NO./LAB NO.	:012502130009
EFERRED BY	:	REGIS	TRATION DATE	: 13/Feb/2025 09:12 AM
ARCODE NO.	: 01525415	COLLI	ECTION DATE	: 13/Feb/2025 09:16AM
LIENT CODE.	: KOS DIAGNOSTIC LAB		RTING DATE	: 13/Feb/2025 11:16AM
LIENT ADDRESS	: 6349/1, NICHOLSON ROA	AD, AMBALA CANTT		
'est Name		Value	Unit	Biological Reference interval
	CLIN	NICAL CHEMISTRY GLUCOSE FAST		Y
TERPRETATION ACCORDANCE WIT A fasting plasma g A fasting plasma g st (after consumpt	H AMERICAN DIABETES ASSOC lucose level below 100 mg/dl lucose level between 100 - 12 ion of 75 ams of alucose) is re	is considered normal. 25 mg/dl is considered as gl commended for all such pat	lients.	NORMAL: < 100.0 PREDIABETIC: 100.0 - 125.0 DIABETIC: > 0R = 126.0 ediabetic. A fasting and post-prandial blood post-prandial is strongly recommended for a ory for diabetic state.
en patients. A last				
		*** End Of Report	* * *	
		*** End Of Report	* * *	

KOS Diagnostic Lab (A Unit of KOS Healthcare)





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

